Jame Abraham, Enterprise Chairman and Professor at the Department of Hematology and Medical Oncology at Cleveland Clinic, shared on X:
“A new chapter in HER2+ breast cancer.
From trastuzumab to dual blockade, TKIs, and ADCs, and now bispecific antibodies.
885 patients with untreated HER2+ advanced breast cancer were randomized to anbenitamab (HER2 bispecific) + nab-docetaxel vs THP.
- 24-mo PFS: 58.5% vs 34.4%
- HR 0.46 (95% CI 0.37–0.56)
- ORR: 87.6% vs 73.4%
- Benefit across all subgroups
- More grade ≥3 AEs (45.9% vs 34.4%), mostly neutropenia; severe diarrhea and ILD were low
OS is still immature, the trial was China-only, and the comparator was THP rather than T-DXd + pertuzumab.
Global validation is next. Most importantly, this is amazing news for patients newly diagnosed with HER2+ metastatic breast cancer.
Kudos to Prof. Binghe Xu, the Chinese investigators, and the patients who made this possible.”
You can also read:
